Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flortaucipir PET in AD Phases (AIBL)
NCT04468347Phase 1Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Oct 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of flortaucipir in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (4 arms), sponsored by Avid Radiopharmaceuticals. Primary endpoints: Flortaucipir PET Imaging (Quantitative), Number of Participants With Advanced AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status and 1 more. Started Oct 2014; status: completed.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04468347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04468347.